Article info
PDFClinical and epidemiological research
Extended report
Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
- Correspondence to Joachim Sieper, University Clinic Benjamin Franklin, Medical Department I, Rheumatology, PO Box, Berlin 12200, Germany; joachim.sieper{at}charite.de
Citation
Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
Publication history
- Received June 24, 2011
- Accepted October 9, 2011
- First published November 29, 2011.
Online issue publication
November 02, 2019
Article Versions
- Previous version (2 November 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This paper is freely available online under the BMJ Journals unlocked scheme, see http://ard.bmj.com/info/unlocked.dtl